Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

16 17 18 19 20

Self-Selected Individual Music Therapy for Depression during Hospitalization for Cancer Patients: Randomized Controlled Clinical Trial Study Widiyono Widiyono; Sri Setiyarini; Christantie Effendy
Indonesian Journal of Cancer Vol 13, No 3 (2019): September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Depression is a psychological distress that often occurs on cancer patients. Depression can increase patient perception about pain, resulting reduced drug efficacy and longer length of stay. Drug treatment for depression sometimes has side effects. Another intervention to decrease depression on cancer patients is music therapy. Music therapy might avoid polypharmacy in cancer patients. The purpose of this study was to determine the effects of self-selected individual music therapy toward depression of cancer patients.Methods: The method used in this study was the randomized control trial (RCT). Simple Random Sampling was assigned randomly by three researcher assistants to participants (N=70) of intervention and control group. The intervention used was self-selected individual music therapy (SeLIMuT). SeLIMuT was applied four times in 2 days with a duration of 15 minutes each session. Beck Depression Inventory (BDI) was employed for selection purposes. The data were analyzed using Mann-Whitney with p < 0.05 and 95% CI. The effectiveness of therapy was analyzed by the effect size test using abs r.Results: Based on the result of the bivariate analysis, there was an effect of giving self-selected individual music therapy to reduce depression with depression gap in both groups with p-value of 0.001 (p < 0.05). The value of the effect test obtained abs r = 0.82 (r > 0.5). At the end, the self-selected individual music therapy had moderate effect toward depression of cancer patients.Conclusions: Music therapy is safe, inexpensive, and easy to use, for and by patients. The nurse can safely recommend any of these interventions for depression on cancer patients. Specific selections or types of music may have different effects on different patients and may provide different effects at different time, so the use of self-selected individual music therapy is recommended.

Gejala Klinis Neurologis dan Gambaran CT Scan Otak Pasien Kanker Paru Karsinoma Bukan Sel Kecil Metastasis ke Otak di Rumah Sakit Persahabatan DIAN YULIANTI; ELISNA SYAHRUDDIN; AHMAD HUDOYO; AZIZA ICKSAN
Indonesian Journal of Cancer Vol 4, No 1 (2010): Jan - Mar 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i1.78

Brain is one of the common sites of distant metastasis in patients of lung cancer, and incidens of brain metastasis in lung cancer is considered high. In Non-small Cell lung cancer guide line, brain CT done if the neurological symptom occured. Therefore analysis of diagnostic approach related to brain metastases is needed. Prospective analysis of 35 patients newly diagnosed cases of brain metastases in NSCLC. Cross sectional study with additional analysis to find relationship of clinical symptom to result of CT brain over periode July 2008-August 2009 in Persahabatan Hospital. Data were analysed as regards to the presence/absence of neurogical symtomps. Prognostic approach was applied to analyze survival rate.We found that 85,7% patients brain metastases with neurological symptomatic and 14,3% asymptomatic. Five (14,3%) patients with more than one neurologycal symptoms. Depend on stage and cell type of which 27 (77,1%) with adenocarcinoma, 21 (62,9%) with T4, 17 (48,6%) N0 and patients with soliter nodule 8 (22,9%). Theres no correlation between neurologycal symptom and brain metastases. Median survival time of lung cancer patients with brain metastases are 11 month. The majority lung cancer patients with brain metastasis have neurological symptoms. The most brain metatases found in patient with adenocarcinoma, T4 and N0. Median survival was increased in treated patients Keywords: Lung cancer, NSCLC, Brain metastases, Neurological symptoms

Ekspresi Protein Gen p53 yang Bermutasi pada Jaringan Sediaan Blok Parafin Kanker Paru Karsinoma Bukan Sel Kecil ARIF R HANAFI; ELISNA SYAHRUDDIN; AHMAD HUDOYO
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i3.101

The tumor supressor gen p53 mutation encodes a protein that inhibits programmed cell death (apoptosis). The protein is expressed in basal cells in normal human epithelium, but no data are available on the frequency or clinical importance of its expression in carcinoma. We studied p53 mutation protein expression in post surgery tissues of patients with non-small cell lung carcinoma (NSCLC) and evaluated the correlation between protein expressions with prognosis of diseases. We have performed a retrospective study using 43 parafin block samples of NSCLC patients who were underwent surgery in Persahabatan Hospital during 1997 to 2008. The p53 mutation protein expression were analyzed by immunohystochemical method using a monoclonal antibody specific for p53 mutation protein. The possibility that p53 mutation expression correlated with survival was investigated with the log-rank test Kaplan Meier. Patients characteristic we found male 25/43 (58.1%) female 18/43 (41.9%) with mean age 56.19 + 8.3 y.o and mostly age 40 to 60 y.o 33/43 (76.7%). Number of smoker patiens were 31/43 (72.1%). We also detected p53 mutation protein in 16/43 (37,2%) in NSCLC tissues. Regarding histopatology types were 9/18 (50%) in squamous-cell carcinomas and 7/25 (28%) in adenocarcinomas. The corellation between positive p53 mutation protein expressions with pathological staging was significant p 0,004, according to T status T1-T2 62,5% and T3-T4 23,8% have had positive p53 mutation protein. Favorable prognostic significance of p53 mutation in patients with NSCLC stage I II, patients in the positive p53 mutataion survived longer than those in negative with respective median survival durations 28 and 18 months p 0,019. Adenocarcinomas type with p53 mutation have had median survival 11 months compared with squamose cell carcinomas 14 months.

The Potential of 9,10-Anthraquinone in Inhibiting Human Cancer Cells Growth Irmanida Batubara; Arif Rakhman Hakim; Silmi Mariya; Suminar Setiati Achmadi; Valentina Sokoastri; Agustin Sri Mulyatni; Rohayati Suprihatini
Indonesian Journal of Cancer Vol 15, No 1 (2021): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: 9,10-Anthraquinone (9,10-AQ) is a contaminant on some agricultural products and considered as carcinogenic based on EU Regulation No. 1146/2014. Except for little evidence on experimental rats, there is no strong proof regarding the carcinogenicity in humans. Therefore, it is essential to find a safe dose of this compound since the difference in 9,10-AQ levels will affect cancer cell growth. This research aims to find the 9,10-AQ concentration that does not proliferate the human cancer cells under in vitro study.Methods: In determining the 9,10-AQ concentration that does not proliferate the cancer cells growth, 0.01 to 500 mg/L 9,10-AQ was directly tested on four human cancer cells (colorectal carcinoma HCT 116, colon adenocarcinoma WiDr, breast cancer MCF-7, and cervical cancer HeLa), and the viability of the cells was counted via (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay. In the gene expression level, the effects on a selected cancer cell line were determined by qRT-PCR against BAX, BCL-2, PCNA, and P53.Results: The result indicates that 9,10-AQ up to 500 mg/L concentration does not proliferate the cell’s growth but instead inhibits those four cancer cells’ growths. The concentration of 9,10-AQ that inhibits 50% the cancer cells growth (IC50) value was 321.8 mg/L (1.55 mM) against HCT 116 and above 500 mg/L (above 2.40 mM) against WiDr, MCF-7, and HeLa. The 9,10-AQ at 500 mg/L (or 2.40 mM) increases BAX expression and acts as an apoptotic agent on HeLa cells.Conclusions: The investigation has shown that 9,10-AQ up to 500 mg/L concentration does not proliferate the cancer cell growth; instead, it inhibits the HCT 116 and HeLa cells growth. We have preliminary evidence regarding the apoptotic mechanism of 9,10-AQ by increasing BAX gene expression on HeLa cells.

Perbedaan Ekspresi HBME-1 dan E-Cadherin pada Nodular Hiperplasia, Karsinoma Papiler, dan Folikular Tiroid PRIMA ROOSANDRIS; ETTY HARY KUSUMASTUTI; NILA KURNIASARI
Indonesian Journal of Cancer Vol 11, No 4 (2017): October- December 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Thyroid lesion can be neoplastic and non neoplastic, whether benign or malignant. There are some cases in which pathologists have difficulties to differentiated those lesions. Aim: To analyze the expression of HBME-1 and E-cadherin on nodular hyperplasia, papillary carcinomas and follicular carcinomas. Paraffin blocks of nodular hyperplasia, papillary carcinoma and follicular thyroid were collected from Departement of Pathology Dr Soetomo General Hospital from January 1st, 2012 to December 31th, 2014. Immunohistochemical staining for HBME-1 and E-cadherin were performed. The difference of expression HBME-1 and E-cadherin were analyzed by Mann Whitney test, and the correlation between HBME-1 and E-cadherin determined using Spearman test. There were significant difference of HBME-1 expression between Nodular hyperplasia and Thyroid carcinoma(p≤0,05). There were also significant difference of HBME-1 between papillary and follicular carcinoma thyroid(p≤0,05). There were no significant difference of E-cadherin expression between Nodular hyperplasia and Thyroid carcinoma(p≥0,05). Conclusion: HBME-1 can be used as a marker to distinguish benign and malignant lesion of thyroid gland, and also to distinguish papillary carcinoma and follicullar carcinoma thyroid. ABSTRAK Lesi tiroid dapat berupa lesi non-neoplastik dan neoplastik, baik jinak maupun ganas. Membedakan tumor tiroid jinak dan ganas sangat penting untuk penatalaksanaan klinis yang tepat sehingga sering kali patolog menemui kesulitan dalam membedakan lesi tiroid jinak dan ganas. Penelitian ini bertujuann membuktikan adanya perbedaan ekspresi HBME-1 dan E-cadherin antara nodular hiperplasi, karsinoma papiler, dan karsinoma folikular tiroid. Dilakukan pemeriksaan imunohistokimia pada blok parafin dari nodular hiperplasia, karsinoma papiler, dan karsinoma folikular yang tersimpan di Instalasi Patologi Anatomi RSUD Dr. Soetomo (1 Januari 2012 sampai dengan 31 Desember 2014 sebanyak 35 sampel sesuai kriteria inklusi) dengan antibodi HBME-1 dan E-cadherin. Ekspresi HBME-1 dan E-cadherin dianalisis dengan uji Mann Whitney, sedangkan korelasi antara HBME-1 dan E-cadherin diuji dengan Spearman Test. Hasil penelitian menunjukkan terdapat perbedaan ekspresi HBME-1 yang signifikan antara nodular hiperplasia dan karsinoma tiroid( p≤0,05); terdapat perbedaan ekspresi HBME-1 yang signifikan antara karsinoma papiler tiroid dan karsinoma folikular tiroid (p≤0,05). Tidak terdapat perbedaan ekspresi E-cadherin yang signifikan pada nodular hiperplasi dan karsinoma tiroid (p≥0,05). Penelitian ini menyimpulkan bahwa HBME-1 dapat digunakan sebagai marker untuk mebedakan lesi jinak dan ganas kelenjar tiroid, serta dapat digunakan untuk membedakan karsinoma papiler tiroid dan karsinoma folikular tiroid.

Metoda-metoda untuk Mendeteksi Adanya Infeksi HPV Bambang Dwipoyono
Indonesian Journal of Cancer Vol 2, No 2 (2008): Apr - Jun 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Usaha menurunkan insiden dan prevalenjuga kematian kanker serviks uteri adalah dengan menemukannya di populasi perempuan yang dikenal sebagai deteksi dini. Beberapa metoda menemukan sel-sel prekanker maupun kanker sudah dikenal sejak cukup lama, yang awalnya berbasis pada sitologik. Dengan majunya pengetahuan tentang perjalanan alamiah penyakit maupun makin berkembangnya teknologi biologi melekular maka ditemukannya teknik-teknik lain yang lebih baik secara sensitifitas maupun spesifitasnya. Setiap metoda mempunyai nilai diagnostiknya sendiri-sendiri, sehingga pemilihannya disesuaikan dengan kebutuhan yang diinginkan.Kata kunci: metoda, deteksi, HPV

The Association Between Knowledge and Preventive Behavior of Cervical Cancer Among Woman Employees in The Companies in Jakarta Febri Hardiyanti; Johan Harlan; Ema Hermawati
Indonesian Journal of Cancer Vol 14, No 1 (2020): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Cervical cancer is the second most frequent malignant tumor among women in the world and the most common type of cancer found among women in developing countries, including Indonesia. It has been predicted that the number of people who have this cancer will increase in the future due to lifestyle changes. The study aims to determine the association between the knowledge and the preventive behavior of cervical cancer among woman employees in the companies in Jakarta. Methods: This research is a quantitative analytical study, with a cross-sectional design. The purposive sampling method was performed to choose the respondents, who are the employees of 3 companies in Jakarta. One hundred married women were selected as the research respondents, namely 32 ET employees, 37 BTI employees, and 31 AT employees. The data were collected using the questionnaires on the knowledge of cervical cancer as an independent variable and the preventive behavior of cervical cancer as a dependent variable. The data collection was conducted from March to April. The statistical trial analysis was performed with the Chi-Square test. Results: From the results of the research, it was found that 74% of the employees have enough preventive behavior of cervical cancer. A total of 73% of employees have good cervical cancer knowledge. The Chi-square test between the knowledge and preventive behavior of cervical cancer obtains P=.043 ; OR 3.68, 95% CI 1.005–13.474. It means there is an association between the knowledge and the preventive behavior of cervical cancer among woman employees in the companies in Jakarta. Conclusions: Good cervical cancer knowledge is significantly associated with good cervical cancer preventive behavior among woman employees in the companies in Jakarta.

Predicting Normal Tissue Radiotoxicity in Radiotherapy Patients Based on the Individual Radiosensitivity Using Three-Color Fluorescence In Situ Hybridization: A Literature Review Dwi Ramadhani; Isnaini Farida; Arum Wulansari; Wiwin Mailana; Hartini Ahadiyatur Ru’yi; Syarifatul Ulya; Sofiati Purnami; Nastiti Rahajeng; Devita Tetriana; Iin Kurnia; Mukh Syaifudin
Indonesian Journal of Cancer Vol 16, No 2 (2022): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: The variability of clinical response in radiotherapy (RT) patients revealed that individual radiosensitivity exists in humans. Although several techniques for radiosensitivity assessment are available, fluorescence in situ hybridization (FISH) has proven to be the most reliable cytogenetic technique. This study will review the use of three-color FISH to evaluate the individual radiosensitivity in cancer patients, particularly breast and prostate cancer patients. Also, it will explain factors that should be considered when using this assay in RT patients.Methods: We used the “radiosensitivity”, “fluorescence in situ hybridization”, “FISH”, and “cancer” as medical subject headings. Non-English articles were excluded. Only articles written in English with a full-text PDF format could be found and using three-color FISH for individual radiosensitivity prediction in radiotherapy patients as subjects were included in this review.Results: : In total, 1,905 articles were retrieved from PubMed and PubMed Central databases from 1990 to 2020. The articles were screened, and those that met the inclusion criteria and did not meet the exclusion criteria were reviewed. Finally, we evaluated eight articles in this reviewConclusions: Appropriate assays such as three-color FISH for individual radiosensitivity assessment could optimize the effectiveness of RT treatment and predict the severity of normal tissue toxicity reactions in RT patients.

Profil Pasien Kanker Payudara di Rumah Sakit Onkologi Surabaya, 2014 LOELITA MARCELIA LUMINTANG; ADI SUSANTO; RAISSA GADRI; ARIO DJATMIKO
Indonesian Journal of Cancer Vol 9, No 3 (2015): Jul - Sept 2015
Publisher : National Cancer Center - Dharmais Cancer Hospital

The prevalence of breast cancer in developing countries as well as developed countries still occupies in high level. The awareness of breast cancer risk factors can enhance the early detection program. The objective of this research is to achieve a complete description concerning risk factors: social, economy and demography statuses that will be advantageous for integrated prevention program of breast cancer. This descriptive research used 485 datas out of 560 medical records that belonged to Rumah Sakit Onkologi Surabayas new breast cancer patients in 2014. The results of this research showed that 31.34% of breast cancer patients attained in the age of 41-50 years old and 51-60 years old; 41.65% acquired university education, 53.61% lived in Java; 69.69% did not have any history of cancer in their family; 85.36% did not have any history of breast cancer in their family; 57.31% were housewives; 42.27% obesity; 46.19% had been pregnant more than twice; 38.56% gave birth more than twice; 82.06% never used any contraception; 8.66% usedcontraception for 1-5 years; 63.71% breast-feeding; 27.84% breast-feeding to 3 or more children; and 21.03% breastfeeding for 0 to 6 months. There were some risk factors that are detectable and preventable.Prevalensi kanker payudara di negara berkembang dan negara maju masih sangat tinggi. Kesadaran akan faktor risiko kanker payudara dapat meningkatkan peluang untuk melakukan program deteksi dini. Penelitian ini bertujuan untuk mendapatkan gambaran yang lengkap perihal faktor risiko: status sosial, ekonomi, dan demografi yang akan bermanfaat untuk perencanaan program penanggulangan kanker terpadu. Penelitian deskriptif ini menggunakan 485 data dari 560 data rekam medis pasien kanker payudara baru 2014 di Rumah Sakit Onkologi, Surabaya. Hasil penelitian menunjukkan 31,34% pasien berusia 41?50 tahun dan 51?60 tahun; 41,65% berpendidikan universitas; 53,61% bertempat tinggal di Pulau Jawa; 69,69% tidak memiliki riwayat keluarga dengan kanker; 85,36% tidak memiliki riwayat keluarga dengankanker payudara; 57,31% ibu rumah tangga; 42,27% obesitas; 46,19% hamil lebih dari 2 kali; 38,56% melahirkan lebih dari 2 kali; 82,06% tidak pernah menggunakan kontrasepsi; 8,66% menggunakan kontrasepsi selama 1-5 tahun; 63,71% memiliki riwayat menyusui; 27,84% menyusui 3 anak atau lebih; dan 21,03% menyusui selama 0?6 bulan. Didapatkan sejumlah faktor risiko yang dapat diwaspadai serta dicegah.

Penanganan Metastasis Tulang dan Bone Loss pada Penderita Kanker Prostat FERRY SAFRIADI
Indonesian Journal of Cancer Vol 6, No 3 (2012): Jul - Sep 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i3.206

Kanker prostat merupakan keganasan non-kulit terbanyak di negara barat atau keganasan keempat terbanyak pada pria setelah kanker kulit, paru, dan usus besar.Di negara maju, stadium awal ditemukan pada 75% penderita. Di Rumah Sakit Hasan Sadikin, Bandung, pada periode 2004-2010 ditemukan 57% kasus masih terbatas di organ dan locally advanced. Sedangkan sisanya, 43% termasuk stadium lanjut dari 320 kasus kanker prostat.Kanker prostat adalah keganasan di bidang urologi yang paling sering bermetastasis ke tulang sampai 70% kasus. Penyulitnya berupa nyeri hebat, fraktur patologis, sindrom kompresi tulang belakang, dan hiperkalsemia. Insidensi penyulit sekitar 46,1% mengakibatkan peningkatan biaya perawatan dan memperburuk prognosis pasien.Androgen Deprivation Therapy merupakan terapi kanker prostat yang telah bermetastasis. Terapi ini sendiri menyebabkan osteopenia atau osteoporosis.Bifosfonat merupakan obat yang paling banyak dipakai saat ini untuk terapi metastasis tulang. Bifosfonat menghambat secara langsung aktivitas osteoclast dan secara tidak langsung melalui osteoblast. Denosumab merupakan opsi terapi terkini pada kasus metastasis tulang dan lebih baik dari asam zoledronat.Kata kunci: kanker prostat, metastasis tulang, bone loss, terapi.

Page 18 of 57 | Total Record : 562

16 17 18 19 20

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA